A study to compare efficacy and safety of mometasone furoate and fluticasone furoate nasal sprays for treatment of allergic rhinitis in children aged 6-18 years.
Not Applicable
- Conditions
- Health Condition 1: J309- Allergic rhinitis, unspecified
- Registration Number
- CTRI/2022/01/039269
- Lead Sponsor
- Dr Shubham jain
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children between 6 and 18 years of either gender with history of having or diagnosed allergic rhinitis.Allergic rhinitis is characterized by nasal blockage, rhinorrhea, sneezing and itching; any 2 of the above 4 symptoms must be present for >1hr every day for >2weeks to diagnose allergic rhinitis.
Children with allergic rhinitis whose parents could understand and were able to adhere to the dosing and visit schedules and agreed to record the events accurately and consistently.
Exclusion Criteria
Children with any known Comorbid condition.
Children with symptoms of rhinitis with fever.
Children whose parents do not give consent.
Children who are already being treated with intranasal corticosteroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method